U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry UNKNOWN
Molecular Formula C19H25NO2
Molecular Weight 299.4073
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NYLIDRIN

SMILES

CC(CCC1=CC=CC=C1)NC(C)C(O)C2=CC=C(O)C=C2

InChI

InChIKey=PTGXAUBQBSGPKF-UHFFFAOYSA-N
InChI=1S/C19H25NO2/c1-14(8-9-16-6-4-3-5-7-16)20-15(2)19(22)17-10-12-18(21)13-11-17/h3-7,10-15,19-22H,8-9H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C19H25NO2
Molecular Weight 299.4073
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://eci2012.net/product/arlidin/

Nylidrin (Buphenine, Arlidin) is a beta-adrenergic agonist. Nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. It is used in the treatment of peripheral vascular disorders and premature labor. In peripheral vascular disorders, Arlidin (nylidrin HCl) increases walking ability and promotes healing of trophic ulcers. Nylidrin hydrochloride acts predominantly by beta-receptor stimulation. Beta stimulation with nylidrin has been demonstrated in a variety of isolated tissues from rabbits, guinea pigs and dogs. It has been shown to dilate arterioles in skeletal muscle and to increase cardiac output in the anesthetized dog and cat and in unanesthetized man. An increase in cerebral blood flow and a decrease in vascular resistance has also been reported. The result of this combination of actions is a greater blood supply to ischemic tissues, with usually minimal change in blood pressure. Arlidin may be of benefit in elderly patients with mild to moderate symptoms that are commonly associated with organic mental disorders. Short-term (3 months’ duration) and long-term (12 months’ duration) clinical studies have demonstrated a modest improvement in ability to perform general activities of daily living, self-care and in a capability for social interactions. The mechanism whereby nylidrin may provide relief of selected symptoms in some elderly patients with organic brain disorders is not known.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Arlidin

Approved Use

May be of benefit in elderly patients with mild to moderate symptoms that are commonly associated with organic mental disorders.
Primary
Arlidin

Approved Use

Peripheral vascular disease, intermittant claudication, thrombophlebitis, TAO, frost bite, nocturnal leg cramps.
Doses

Doses

DosePopulationAdverse events​
120 mg single, oral
Overdose
Dose: 120 mg
Route: oral
Route: single
Dose: 120 mg
Co-administed with::
chlorothiazide(1 g)
Sources:
unknown, 14 years
n = 1
Health Status: unknown
Age Group: 14 years
Sex: F
Population Size: 1
Sources:
Other AEs: Chest pain, Headache...
Other AEs:
Chest pain (1 patient)
Headache (1 patient)
Flushing (1 patient)
Shortness of breath (1 patient)
Sources:
6 mg 2 times / day multiple, oral
Dose: 6 mg, 2 times / day
Route: oral
Route: multiple
Dose: 6 mg, 2 times / day
Sources:
unhealthy, 32 years
n = 1
Health Status: unhealthy
Condition: unstable angina pectoris
Age Group: 32 years
Sex: M
Population Size: 1
Sources:
50 mg/min multiple, intravenous (starting)
Dose: 50 mg/min
Route: intravenous
Route: multiple
Dose: 50 mg/min
Sources:
pregnant
n = 30
Health Status: pregnant
Sex: F
Population Size: 30
Sources:
AEs

AEs

AESignificanceDosePopulation
Chest pain 1 patient
120 mg single, oral
Overdose
Dose: 120 mg
Route: oral
Route: single
Dose: 120 mg
Co-administed with::
chlorothiazide(1 g)
Sources:
unknown, 14 years
n = 1
Health Status: unknown
Age Group: 14 years
Sex: F
Population Size: 1
Sources:
Flushing 1 patient
120 mg single, oral
Overdose
Dose: 120 mg
Route: oral
Route: single
Dose: 120 mg
Co-administed with::
chlorothiazide(1 g)
Sources:
unknown, 14 years
n = 1
Health Status: unknown
Age Group: 14 years
Sex: F
Population Size: 1
Sources:
Headache 1 patient
120 mg single, oral
Overdose
Dose: 120 mg
Route: oral
Route: single
Dose: 120 mg
Co-administed with::
chlorothiazide(1 g)
Sources:
unknown, 14 years
n = 1
Health Status: unknown
Age Group: 14 years
Sex: F
Population Size: 1
Sources:
Shortness of breath 1 patient
120 mg single, oral
Overdose
Dose: 120 mg
Route: oral
Route: single
Dose: 120 mg
Co-administed with::
chlorothiazide(1 g)
Sources:
unknown, 14 years
n = 1
Health Status: unknown
Age Group: 14 years
Sex: F
Population Size: 1
Sources:
PubMed

PubMed

TitleDatePubMed
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Sample Use Guides

The recommended dose of nylidrin is 12 mg to 24 mg daily in 3 or 4 divided doses for certain types of mental disorders. For blood vessel disorders of the legs, the recommended adult dose is 12 mg to 48 mg daily in 3 to 4 divided doses.
Route of Administration: Oral
In Vitro Use Guide
Nylidrin was a potent (IC50 = 0.18 uM) antagonist of rat NR1A/2B receptors expressed in Xenopus oocytes
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:35:38 UTC 2023
Edited
by admin
on Sat Dec 16 16:35:38 UTC 2023
Record UNII
695DKH33EI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NYLIDRIN
HSDB   MI   VANDF  
Common Name English
P-HYDROXY-.ALPHA.-(1-((1-METHYL-3-PHENYLPROPYL)AMINO)ETHYL)BENZYL ALCOHOL
Common Name English
BUPHENIN
Common Name English
BENZENEMETHANOL, 4-HYDROXY-.ALPHA.-(1-((1-METHYL-3-PHENYLPROPYL)AMINO)ETHYL)-
Systematic Name English
BUPHENINE
INN   WHO-DD  
INN  
Official Name English
Buphenine [WHO-DD]
Common Name English
NYLIDRIN [VANDF]
Common Name English
buphenine [INN]
Common Name English
NYLIDRIN [MI]
Common Name English
NYLIDRIN [HSDB]
Common Name English
Classification Tree Code System Code
WHO-ATC C04AA02
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
WHO-ATC G02CA02
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
NCI_THESAURUS C48149
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
WHO-VATC QC04AA02
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
WHO-VATC QG02CA02
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
Code System Code Type Description
RXCUI
7595
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY RxNorm
ChEMBL
CHEMBL114655
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY
HSDB
3137
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY
DRUG CENTRAL
1976
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY
WIKIPEDIA
Nylidrin
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY
MESH
D009756
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY
NCI_THESAURUS
C81642
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY
SMS_ID
100000088448
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY
ECHA (EC/EINECS)
207-182-2
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY
DRUG BANK
DB06152
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY
EVMPD
SUB05981MIG
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY
MERCK INDEX
m8091
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY Merck Index
FDA UNII
695DKH33EI
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY
EPA CompTox
DTXSID4023387
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY
CAS
447-41-6
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY
PUBCHEM
4567
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY
INN
461
Created by admin on Sat Dec 16 16:35:38 UTC 2023 , Edited by admin on Sat Dec 16 16:35:38 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY